We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold Syneos Health in Your Portfolio Now
Read MoreHide Full Article
Syneos Health is progressing well with its growth strategies like pursuing collaborations and driving segmental performance. However, a strict regulatory environment and tough competition are likely to offset the positives to some extent.
This leading provider of biopharmaceutical solutions has a market capitalization of $6.73 billion. Its earnings growth rate has been 25.8% for the past five years. Also, the company has a trailing four-quarter positive earnings surprise of 2.7%, on average.
Over the past year, the stock has outperformed its industry. The stock rallied 44.5% compared with the industry’s 10% rise.
Let’s delve deeper into the other factors that justify the company’s Zacks Rank #3 (Hold).
Balanced Segmental Growth: Syneos Health witnessed solid sales growth across all segments in the just-reported fourth quarter. The Clinical Solutions segment service revenue growth was 9.5% year over year, driven by higher revenues from net new business awards and increased reimbursable expenses. Within the Commercial Solutions segment, yearly revenues grew 6.3% on higher revenues from net new business awards, including European expansion and the acquisition of Kinapse. The encouraging trend is expected to continue in the near future.
Partnerships to Add Value: Last November, Syneos Health inked a partnership deal with AiCure (an AI and advanced data analytics company) for faster and smarter trials to optimize patient engagement.In January 2020, Syneos Health inked a collaboration and minority investment deal with Indegene Omnipresence and the company’s next-generation unified customer experience platform. These partnerships are expected to be driving growth for the company throughout 2020.
Syneos One Holds Potential: Syneos One coordinates integrated solutions across the entire clinical development and commercialization processes. Syneos Health aims at accelerating commercial outsourcing with Syneos One. The company is optimistic about the continuation and growth of customer interest in Syneos One.
However, there are a few downsides marring the company’s prospects.
Strict Regulatory Environment:Thebiopharmaceutical industry is governed by extremely stringent governmental regulation in both domestic and global markets. Within the Clinical Solutions business, the FDA regulates the clinical trials of drug products in human enrollments, the form and content of regulatory applications. Globally, the clinical trials are governed by the laws and regulations of the country where those are conducted.
Tough Competitive Landscape: Syneos Health operates in a highly competitive environment, dominated by firms varying from large CROs and smaller specialty CROs, large global communications holding companies, smaller specialized communications agencies, contract sales organizations and a wide range of consulting companies.
Estimate Trend
The company is witnessing a positive estimate revision trend for 2020 earnings. Over the past seven days, the Zacks Consensus Estimate for 2020 earnings has inched up 0.8% to $3.69 per share.
The consensus estimate for the company’s first-quarter 2020 revenues is pegged at $1.15 billion, suggesting a 3.2% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , Medtronic plc (MDT - Free Report) and Hill-Rom Holdings, Inc. .
Medtronic’s long-term earnings growth rate is estimated at 7.4%. The company presently carries a Zacks Rank #2 (Buy).
Hill-Rom’s long-term earnings growth rate is projected at 11.1%. It currently carries a Zacks Rank #2.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Here's Why You Should Hold Syneos Health in Your Portfolio Now
Syneos Health is progressing well with its growth strategies like pursuing collaborations and driving segmental performance. However, a strict regulatory environment and tough competition are likely to offset the positives to some extent.
This leading provider of biopharmaceutical solutions has a market capitalization of $6.73 billion. Its earnings growth rate has been 25.8% for the past five years. Also, the company has a trailing four-quarter positive earnings surprise of 2.7%, on average.
Over the past year, the stock has outperformed its industry. The stock rallied 44.5% compared with the industry’s 10% rise.
Let’s delve deeper into the other factors that justify the company’s Zacks Rank #3 (Hold).
Balanced Segmental Growth: Syneos Health witnessed solid sales growth across all segments in the just-reported fourth quarter. The Clinical Solutions segment service revenue growth was 9.5% year over year, driven by higher revenues from net new business awards and increased reimbursable expenses. Within the Commercial Solutions segment, yearly revenues grew 6.3% on higher revenues from net new business awards, including European expansion and the acquisition of Kinapse. The encouraging trend is expected to continue in the near future.
Partnerships to Add Value: Last November, Syneos Health inked a partnership deal with AiCure (an AI and advanced data analytics company) for faster and smarter trials to optimize patient engagement.In January 2020, Syneos Health inked a collaboration and minority investment deal with Indegene Omnipresence and the company’s next-generation unified customer experience platform. These partnerships are expected to be driving growth for the company throughout 2020.
Syneos One Holds Potential: Syneos One coordinates integrated solutions across the entire clinical development and commercialization processes. Syneos Health aims at accelerating commercial outsourcing with Syneos One. The company is optimistic about the continuation and growth of customer interest in Syneos One.
However, there are a few downsides marring the company’s prospects.
Strict Regulatory Environment:Thebiopharmaceutical industry is governed by extremely stringent governmental regulation in both domestic and global markets. Within the Clinical Solutions business, the FDA regulates the clinical trials of drug products in human enrollments, the form and content of regulatory applications. Globally, the clinical trials are governed by the laws and regulations of the country where those are conducted.
Tough Competitive Landscape: Syneos Health operates in a highly competitive environment, dominated by firms varying from large CROs and smaller specialty CROs, large global communications holding companies, smaller specialized communications agencies, contract sales organizations and a wide range of consulting companies.
Estimate Trend
The company is witnessing a positive estimate revision trend for 2020 earnings. Over the past seven days, the Zacks Consensus Estimate for 2020 earnings has inched up 0.8% to $3.69 per share.
The consensus estimate for the company’s first-quarter 2020 revenues is pegged at $1.15 billion, suggesting a 3.2% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , Medtronic plc (MDT - Free Report) and Hill-Rom Holdings, Inc. .
ResMed has a projected long-term earnings growth rate of 12%. It currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Medtronic’s long-term earnings growth rate is estimated at 7.4%. The company presently carries a Zacks Rank #2 (Buy).
Hill-Rom’s long-term earnings growth rate is projected at 11.1%. It currently carries a Zacks Rank #2.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>